SALKA SUSAN R

SEC source: 0001209191-19-055593 · doc4.xml · nonDerivative · entry 1

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 131,555

F1 · kind: The sale of 18,156 shares of Common Stock reported in this row was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in this row represents a weighted average price of $60.1897 per share. These shares were sold in multiple transactions at prices ranging from $59.98 to $60.81, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-19-045186 · doc4.xml · nonDerivative · entry 1

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,711

F1 · kind: The sale of 45,975 shares of AMN Common Stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in this row represents a weighted average price of $49.9247 per share. These shares were sold in multiple transactions at prices ranging from $49.50 to $50.49, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001598100-19-000006 · edgar.xml · derivative · entry 1

SALKA SUSAN R · CIK 0001158584 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,296

Underlying: Common Stock · 1,296 shares

Expires not disclosed

F1 · derivative.exercise_date: RSUs granted pursuant to an automatic annual grant under the 2013 Stock Plan. This grant vests immediately, however, receipt of the underlying shares is deferred until the Director leaves the Board.

F1 · derivative.expiration_date: RSUs granted pursuant to an automatic annual grant under the 2013 Stock Plan. This grant vests immediately, however, receipt of the underlying shares is deferred until the Director leaves the Board.

SEC source: 0001209191-19-030406 · doc4.xml · derivative · entry 5

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 58,184 shares

Expires 2020-02-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: The exercise of derivative securities reported in this row was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F6 · derivative.exercise_date: The SSARs set forth in this row were granted on February 2, 2010 pursuant to the AMN Healthcare Equity Plan and vested in three equal installments on the first, second and third anniversary of the grant date.

SEC source: 0001209191-19-030406 · doc4.xml · nonDerivative · entry 4

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 195,686

F3 · kind: The sale of 29,179 shares of Stock set forth in this row was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in this row represents a weighted average price of $51.0238 per share. These shares were sold in multiple transactions at prices ranging from $50.67 to $51.31, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-19-030406 · doc4.xml · nonDerivative · entry 3

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 224,865

F2 · shares: A Stock-Settled Appreciation Right ("SSAR") entitles the Grantee to the right to receive shares of AMN's Common Stock ("Stock") having a value equal to the excess of the Fair Market Value of the closing price of the Stock on the trading day prior to the date of exercise over the Exercise Price multiplied by the number of SSARs exercised. The number set forth in this row represents the difference between the number of SSARs exercised (58,184), and the number of shares of Stock issued as a result of the exercise (29,179).

SEC source: 0001209191-19-030406 · doc4.xml · nonDerivative · entry 2

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 253,870

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-19-030406 · doc4.xml · nonDerivative · entry 1

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 195,686

F1 · kind: The reporting person transferred 12,000 shares of AMN Common Stock as gifts to charities.

SEC source: 0001209191-19-020971 · doc4.xml · derivative · entry 4

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,184

Underlying: Common Stock · 58,185 shares

Expires 2020-02-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: The exercise of derivative securities reported in this row was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · derivative.exercise_date: The SSARs set forth in this row were granted on February 2, 2010 pursuant to the AMN Healthcare Equity Plan and vested in three equal installments on the first, second and third anniversary of the grant date.

SEC source: 0001209191-19-020971 · doc4.xml · nonDerivative · entry 3

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,686

F2 · kind: The sale of 28,746 shares of Stock set forth in this row was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in this row represents a weighted average price of $48.048 per share. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.28, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-19-020971 · doc4.xml · nonDerivative · entry 2

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,432

F1 · shares: A Stock-Settled Appreciation Right ("SSAR") entitles the Grantee to the right to receive shares of AMN's Common Stock ("Stock") having a value equal to the excess of the Fair Market Value of the closing price of the Stock on the trading day prior to the date of exercise over the Exercise Price multiplied by the number of SSARs exercised. The number set forth in this row represents the difference between the number of SSARs exercised (58,185), and the number of shares of Stock issued as a result of the exercise (28,746).

SEC source: 0001209191-19-020971 · doc4.xml · nonDerivative · entry 1

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 265,871

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-19-012090 · doc4.xml · derivative · entry 8

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,687

Underlying: Common Stock · 6,742 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_price: The RSUs identified in this row were granted pursuant to the AMN Healthcare 2017 Equity Plan. Each RSU represents a contingent right to receive one share of AMN Common Stock.

F9 · derivative.exercise_date: The RSUs identified in this row were granted on December 19,2017 and vest on the third anniversary of the grant date, provided, however, the RSUs shall vest on an accelerated basis thirteen months after the grant date, in the incremental amount of 33%, should the Company achieve or exceed a certain specified earnings before interest, taxes, depreciation and amortization (EBITDA) target for the 2018 fiscal year, and on the second anniversary of the grant date, in the amount of 34%, should the Company achieve or exceed the specified EBITDA target for the 2019 fiscal year.

F7 · derivative.expiration_date: RSUs do not have an expiration date.

SEC source: 0001209191-19-012090 · doc4.xml · derivative · entry 7

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,872

Underlying: Common Stock · 10,172 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: The RSUs identified in this row were granted pursuant to the AMN Healthcare Equity Plan. Each RSU represents a contingent right to receive one share of AMN Common Stock.

F6 · derivative.exercise_date: The RSUs identified in this row were granted on December 5, 2016 and vest on the third anniversary of the grant date, provided, however, the RSUs shall vest on an accelerated basis thirteen months after the grant date, in the incremental amount of 33%, should the Company achieve or exceed a certain specified earnings before interest, taxes, depreciation and amortization (EBITDA) target for the 2017 fiscal year, and on the second anniversary of the grant date, in the amount of 34%, should the Company achieve or exceed the specified EBITDA target for the 2018 fiscal year.

F7 · derivative.expiration_date: RSUs do not have an expiration date.

SEC source: 0001209191-19-012090 · doc4.xml · nonDerivative · entry 6

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,686

F2 · kind: Number of shares withheld for tax purposes.

SEC source: 0001209191-19-012090 · doc4.xml · nonDerivative · entry 5

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,338

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: Common Stock acquired on the vesting of RSUs.

SEC source: 0001209191-19-012090 · doc4.xml · nonDerivative · entry 4

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 203,596

F2 · kind: Number of shares withheld for tax purposes.

SEC source: 0001209191-19-012090 · doc4.xml · nonDerivative · entry 3

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,598

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: Common Stock acquired on the vesting of Restricted Stock Units ("RSUs").

SEC source: 0001209191-19-012090 · doc4.xml · nonDerivative · entry 2

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,426

F2 · kind: Number of shares withheld for tax purposes.

SEC source: 0001209191-19-012090 · doc4.xml · nonDerivative · entry 1

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 203,615

F1 · kind: The acquisition of Common Stock set forth in this row resulted from the vesting of a Performance Restricted Stock Unit ("PRSU") award granted by the Company on January 5, 2016. The ultimate number of PRSUs that could have been earned and vested under this award depended on the Company achieving or exceeding, on a consolidated basis, a certain specified adjusted earnings before interest, taxes, depreciation and amortization, divided by gross revenue and expressed as a percentage ("Adjusted EBITDA Margin") as of December 31, 2018 for the one-year period beginning on January 1, 2018 and ended December 31, 2018. As a result, 77.50% of the target amount of PRSUs for this award were deemed earned and vested.

SEC source: 0001209191-19-002919 · doc4.xml · derivative · entry 6

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,369

Underlying: Common Stock · 77,580 shares

Expires 2020-02-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · kind: The exercise of derivative securities reported in this row was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F7 · derivative.exercise_date: The SSARs set forth in this row were granted on February 2, 2010 pursuant to the AMN Healthcare Equity Plan and vested in three equal installments on the first, second and third anniversary of the grant date.

SEC source: 0001209191-19-002919 · doc4.xml · nonDerivative · entry 5

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,886

F4 · kind: The sale of 39,552 shares of AMN Common Stock set forth in this row was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · price: The price reported in this row represents a weighted average price of $57.8953 per share. These shares were sold in multiple transactions at prices ranging from $57.305 to $58.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-19-002919 · doc4.xml · nonDerivative · entry 4

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 227,438

F3 · shares: A Stock-Settled Appreciation Right ("SSAR") entitles the Grantee to the right to receive shares of AMN's Common Stock ("Stock") having a value equal to the excess of the Fair Market Value of the closing price of the Stock on the trading day prior to the date of exercise over the Exercise Price multiplied by the number of SSARs exercised. This number set forth in this row represents the difference between the number of SSARs exercised (77,580) and the number of shares of Stock issued as a result of the exercise (39,552).

SEC source: 0001209191-19-002919 · doc4.xml · nonDerivative · entry 3

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 265,466

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-19-002919 · doc4.xml · nonDerivative · entry 2

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,886

F2 · kind: Number of shares withheld for tax purposes.

SEC source: 0001209191-19-002919 · doc4.xml · nonDerivative · entry 1

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,707

F1 · kind: The acquisition of common stock set forth in this row resulted from the vesting of a Performance Restricted Stock Unit ("PRSU") award granted by the Company on January 5, 2016. The ultimate number of PRSUs that could have been earned and vested under this award depended on (1) the total shareholder return for the Company relative to the companies in the Russell 2000 Index as of December 31, 2015 for the 3-year period beginning on January 1, 2016 and ended December 31, 2018 ("Relative TSR") and (2) whether the Company's absolute total shareholder return for the same period was positive or negative (collectively, the "TSR Measurement"). The Compensation Committee performed the TSR Measurement for this award on January 3, 2019. The Company's Relative TSR measured in the 84th percentile and its absolute total shareholder return for the period was positive. Based on these results, the maximum amount of PRSUs for this award, were deemed earned and vested.

SEC source: 0001209191-19-001808 · doc4.xml · derivative · entry 3

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 42,096 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: The PRSUs set forth in this row were granted pursuant to the AMN Healthcare Equity Plan. Each PRSU represents a contingent right to receive one share of AMN Common Stock.

F4 · derivative.exercise_date: The PRSUs set forth in this row resulted from the vesting of a PRSU award granted by the Company on January 3, 2014. On January 4, 2017, the maximum number of PRSUs that could have been earned, 42,096, were deemed earned and vested under this January 3, 2014 PRSU award.

F5 · derivative.expiration_date: PRSUs do not have an expiration date.

SEC source: 0001209191-19-001808 · doc4.xml · nonDerivative · entry 2

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,957

F2 · kind: Number of shares withheld for tax purposes.

SEC source: 0001209191-19-001808 · doc4.xml · nonDerivative · entry 1

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,885

F1 · kind: The acquisition of AMN Common Stock set forth in this row resulted from the deferred release of a Performance Restricted Stock Unit ("PRSU") award that vested on January 4, 2017. In 2014, the reporting person elected to defer receipt of these PRSUs pursuant to the Company's deferred compensation plan, with a settlement date of January 2, 2019.

SEC source: 0001209191-18-063508 · doc4.xml · derivative · entry 2

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,187

Underlying: Common Stock · 22,187 shares

Expires not disclosed

F2 · derivative.exercise_price: The Restricted Stock Units ("RSUs") set forth in this row were granted pursuant to the AMN Healthcare 2017 Equity Plan. Each RSU represents a contingent right to receive one share of AMN Common Stock.

F3 · derivative.exercise_date: The RSUs were granted on December 17, 2018 and vest in three tranches on each of the first, second and third anniversaries of the grant date and the grantee's provision of three periods of credited service.

F4 · derivative.expiration_date: RSUs do not have an expiration date.

SEC source: 0001209191-18-057352 · doc4.xml · nonDerivative · entry 1

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,789

F1 · kind: The sale of 11,953 shares of Common Stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in this row represents a weighted average price of $56.4871 per share. These shares were sold in multiple transactions at prices ranging from $55.60 to $58.21, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001443873-18-000025 · edgar.xml · derivative · entry 1

SALKA SUSAN R · CIK 0001158584 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,350

Underlying: Common Stock · 1,350 shares

Expires not disclosed

F1 · derivative.exercise_date: RSUs granted pursuant to an automatic annual grant under the 2013 Stock Plan. This grant vests immediately, however receipt of the underlying shares is deferred until the Director leaves the Board.

F1 · derivative.expiration_date: RSUs granted pursuant to an automatic annual grant under the 2013 Stock Plan. This grant vests immediately, however receipt of the underlying shares is deferred until the Director leaves the Board.

SEC source: 0001209191-18-039128 · doc4.xml · nonDerivative · entry 1

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,742

F1 · kind: The sale of 20,000 shares of AMN Common Stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in this row represents a weighted average price of $60.1698 per share. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.40, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-18-030208 · doc4.xml · nonDerivative · entry 1

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,742

F1 · kind: The sale of 20,376 shares of Common Stock reported in this row was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in this row represents a weighted average price of $56.1861 per share. These shares were sold in multiple transactions at prices ranging from $56.35 to $56.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-18-029363 · doc4.xml · nonDerivative · entry 2

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 206,118

F2 · kind: The sale of 31,907 shares of Common Stock reported in this row was also effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in this row represents a weighted average price of $54.6306 per share. These shares were sold in multiple transactions at prices ranging from $54.00 to $55.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-18-029363 · doc4.xml · nonDerivative · entry 1

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 238,025

F1 · kind: The sale of 45 shares of Common Stock reported in this row was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-063508 · doc4.xml · nonDerivative · entry 1

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 143,789

F1 · kind: The reporting person transferred 10,000 shares of AMN Common Stock as a gift to charity.

SEC source: 0001209191-18-011642 · doc4.xml · derivative · entry 6

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,042

Underlying: Common Stock · 11,377 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: The RSUs identified in this row were granted pursuant to the AMN Healthcare Equity Plan. Each RSU represents a contingent right to receive one share of Common Stock.

F7 · derivative.exercise_date: The deferred RSUs identified in this row were granted on December 9, 2015 and vest on the third anniversary of the grant date, provided, however, the RSUs shall vest on an accelerated basis thirteen months after the grant date, in the incremental amount of 33%, should the Company achieve or exceed a certain specified EBITDA target for the 2016 fiscal year, and on the second anniversary of the grant date in the amount of 34%, should the Company achieve or exceed the specified EBITDA target for the 2017 fiscal year.

F6 · derivative.expiration_date: RSUs do not have an expiration date.

SEC source: 0001209191-18-011642 · doc4.xml · derivative · entry 5

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,044

Underlying: Common Stock · 9,873 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: The RSUs identified in this row were granted pursuant to the AMN Healthcare Equity Plan. Each RSU represents a contingent right to receive one share of Common Stock.

F5 · derivative.exercise_date: The RSUs identified in this row were granted on December 5, 2016 and vest on the third anniversary of the grant date, provided, however, the RSUs shall vest on an accelerated basis thirteen months after the grant date, in the incremental amount of 33%, should the Company achieve or exceed a certain specified earnings before interest, taxes, depreciation and amortization ("EBITDA") target for the 2017 fiscal year, and on the second anniversary of the grant date in the amount of 34%, should the Company achieve or exceed the specified EBITDA target for the 2018 fiscal year.

F6 · derivative.expiration_date: RSUs do not have an expiration date.

SEC source: 0001209191-18-011642 · doc4.xml · nonDerivative · entry 4

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 238,070

F2 · kind: Number of shares withheld for tax purposes.

SEC source: 0001209191-18-011642 · doc4.xml · nonDerivative · entry 3

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 241,955

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: Common Stock acquired on the vesting of Restricted Stock Units ("RSUs").

SEC source: 0001209191-18-011642 · doc4.xml · nonDerivative · entry 2

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,082

F2 · kind: Number of shares withheld for tax purposes.

SEC source: 0001209191-18-011642 · doc4.xml · nonDerivative · entry 1

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 249,425

F1 · kind: The acquisition of Common Stock set forth in this row resulted from the vesting of a Performance Restricted Stock Unit ("PRSU") award granted by the Company on January 5, 2015. The ultimate number of PRSUs that could have been earned and vested under this award depended on the Company achieving or exceeding, on a consolidated basis, a certain specified adjusted earnings before interest, taxes, depreciation and amortization, divided by gross revenue and expressed as a percentage ("Adjusted EBITDA Margin") as of December 31, 2017 for the one-year period beginning on January 1, 2017 and ended December 31, 2017. The maximum amount of PRSUs for this award were deemed earned and vested.

SEC source: 0001209191-18-003675 · doc4.xml · nonDerivative · entry 2

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 205,349

F3 · kind: The sale of 16,819 shares of Common Stock reported in this row was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in this row represents a weighted average price of $49.6021 per share. These shares were sold in multiple transactions at prices ranging from $49.05 to $49.90, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-18-003675 · doc4.xml · nonDerivative · entry 1

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 222,168

F1 · kind: The sale of 78,400 shares of Common Stock reported in this row was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in this row represents a weighted average price of $49.3016 per share. These shares were sold in multiple transactions at prices ranging from $48.80 to $49.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-18-002961 · doc4.xml · nonDerivative · entry 2

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,568

F2 · kind: Number of shares withheld for tax purposes.

SEC source: 0001209191-18-002961 · doc4.xml · nonDerivative · entry 1

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 313,636

F1 · kind: The acquisition of Common Stock set forth in this row resulted from the vesting of a Performance Restricted Stock Unit ("PRSU") award granted by the Company on January 5, 2015. The ultimate number of PRSUs that could have been earned and vested under this award depended on (1) the total shareholder return for the Company relative to the companies in the Russell 2000 Index as of December 31, 2014 for the 3-year period beginning on January 1, 2015 and ended December 31, 2017 ("Relative TSR") and (2) whether the Company's absolute total shareholder return for the same period was positive or negative (collectively, the "TSR Measurement"). The Compensation Committee performed the TSR Measurement for this award on January 5, 2018. The Company's Relative TSR measured in the 95th percentile and its absolute total shareholder return for the period was positive. Based on these results, the maximum amount of PRSUs for this award were deemed earned and vested.

SEC source: 0001209191-18-001593 · doc4.xml · derivative · entry 3

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 58,935 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each PRSU represents a contingent right to receive one share of AMN Common Stock.

F4 · derivative.exercise_date: The PRSUs set forth in this row resulted from the vesting of a PRSU award granted by the Company on January 3, 2014. On February 16, 2017, the maximum number of PRSUs that could have been earned, 58,935, were deemed earned and vested under the January 3, 2014 PRSU award.

F5 · derivative.expiration_date: PRSUs do not have an expiration date.

SEC source: 0001209191-18-001593 · doc4.xml · nonDerivative · entry 2

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 282,412

F2 · kind: Number of shares withheld for tax purposes.

SEC source: 0001209191-18-001593 · doc4.xml · nonDerivative · entry 1

SALKA SUSAN R · CIK 0001158584 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 302,785

F1 · kind: The acquisition of AMN Common Stock set forth in this row resulted from the deferred release of a Performance Restricted Stock Unit ("PRSU") award that vested on February 16, 2017. In 2014, the reporting person elected to defer receipt of these PRSUs pursuant to the Company's deferred compensation plan, with a settlement date of January 2, 2018.